gdc-0853
Small moleculeexperimental
Clinical trial activity
10 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT01991184)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gdc-0853
- gdc-0853
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03407482 | Phase 2 | Jan 9, 2018 | Genentech, Roche |
| NCT03137069 | Phase 2 | May 1, 2017 | Roche |
| NCT03290703 | Phase 1 | Apr 18, 2017 | Genentech, Roche |
| NCT03174041 | Phase 1 | Feb 27, 2017 | Genentech, Roche |
| NCT03188783 | Phase 1 | Jan 24, 2017 | Roche |
| NCT02908100 | Phase 2 | Dec 31, 2016 | Genentech, Roche |
| NCT02983227 | Phase 2 | Nov 30, 2016 | Genentech, Roche |
| NCT02833350 | Phase 2 | Sep 9, 2016 | Genentech, Roche |
| NCT02699710 | Phase 1 | Sep 30, 2015 | Genentech, Roche |
| NCT01991184 | Phase 1 | Dec 1, 2013 | Genentech |
Showing 10 of 10 trials
Page 1 / 1